Cooper Companies (COO) delivered a pleasant surprise on Friday, posting fourth-quarter results that topped Wall Street's expectations while simultaneously announcing a strategic review that has investors wondering what changes might be coming.
The medical device company reported adjusted earnings of $1.15 per share for the fourth quarter, an 11% jump from the prior year that beat the consensus estimate of $1.11. Revenue came in at $1.065 billion, essentially matching analyst expectations of $1.061 billion. Overall sales climbed 5% year over year, or 3% on an organic basis.
But the real headline wasn't just the solid numbers—it was what Cooper plans to do next. The company announced it's launching a comprehensive review of its portfolio, structure, strategy, operations, and capital allocation priorities. Translation: everything is on the table. Management is exploring opportunities to streamline the business and unlock additional long-term value, which could include partnerships, joint ventures, divestitures, mergers, or other strategic transactions.
The timing is interesting. Cooper has faced pressure from activist investors questioning its strategic direction and growth strategy, so this review signals management is taking those concerns seriously.
Adding to the shakeup, Cooper announced that Colleen Jay will succeed Robert Weiss as Board Chair effective January 2, 2026.
Breaking Down the Business Segments
Cooper operates two main divisions, and both showed steady growth in the quarter. CooperVision, which focuses on contact lenses, generated $709.6 million in sales—up 5% from the prior-year quarter and 3% in constant currency terms. CooperSurgical, the fertility and women's healthcare division, brought in $355.6 million in revenue, up 4% year over year and 4% organically.
Neither segment is exactly lighting the world on fire with explosive growth, but both are delivering consistent, predictable performance. That's probably part of why management feels comfortable exploring strategic alternatives—the business is stable enough to undergo transformation.
Looking Ahead: Strong Guidance
Cooper's outlook proved even more encouraging than the quarterly results. For the first quarter of fiscal 2026, the company expects sales of $1.019 billion to $1.030 billion versus the consensus of $1.025 billion, with adjusted earnings of $1.02 to $1.04 per share compared to analyst estimates of $1.00.
The full-year fiscal 2026 guidance really got Wall Street's attention. Management projects adjusted earnings of $4.45 to $4.60 per share—significantly above the consensus of $4.09—with revenue expected between $4.299 billion and $4.338 billion versus consensus of $4.089 billion. The company anticipates organic growth of 3% to 4% for the year.
On the cash flow front, Cooper expects to generate $575 million to $625 million in free cash flow during fiscal 2026, with total free cash flow exceeding $2.2 billion from fiscal 2026 through fiscal 2028. That's a substantial cash pile that could fund acquisitions, buybacks, or provide flexibility during any strategic restructuring.
Wall Street Responds
Analysts wasted no time adjusting their outlooks following the announcement. Needham maintained its Buy rating while raising its price target from $94 to $100. Mizuho kept its Outperform rating and boosted its target from $85 to $100. Baird also maintained an Outperform rating, lifting its price forecast from $85 to $98.
Even more cautious analysts saw reason for optimism. JP Morgan maintained a Neutral rating but raised its price target from $66 to $78. Wells Fargo kept its Equal-Weight rating while increasing its forecast from $72 to $82.
Cooper Companies shares rose 7.24% to $82.61 following the announcement, suggesting investors are encouraged by both the strong guidance and the prospect of strategic changes that could unlock additional value.
